A61P 31/06
For tuberculosis
Official title: for tuberculosis
A61P31/06 (For tuberculosis) appears on 2,050 US grants and 3,246 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,050
- Published applications
- 3,246
- Assignees
- 1,347
- Inventors
- 5,817
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 4 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 7 | 0 |
| 1998 | 9 | 0 |
| 1999 | 10 | 0 |
| 2000 | 11 | 0 |
| 2001 | 27 | 6 |
| 2002 | 37 | 51 |
| 2003 | 37 | 80 |
| 2004 | 30 | 116 |
| 2005 | 24 | 129 |
| 2006 | 45 | 108 |
| 2007 | 38 | 123 |
| 2008 | 51 | 124 |
| 2009 | 59 | 166 |
| 2010 | 101 | 325 |
| 2011 | 123 | 237 |
| 2012 | 130 | 217 |
| 2013 | 155 | 161 |
| 2014 | 134 | 172 |
| 2015 | 133 | 158 |
| 2016 | 122 | 136 |
| 2017 | 129 | 135 |
| 2018 | 84 | 121 |
| 2019 | 99 | 127 |
| 2020 | 104 | 125 |
| 2021 | 85 | 100 |
| 2022 | 55 | 88 |
| 2023 | 69 | 76 |
| 2024 | 55 | 71 |
| 2025 | 37 | 62 |
| 2026 | 22 | 32 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Rifamycin analogs and antibody-drug conjugates thereof25 Aug 2026US 12,715,881 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for the detection of tuberculosis25 Aug 2026US 12,716,904 B2Washington University
- Pharmaceutical compositions comprising teixobactin14 Jul 2026US 12,678,479 B2NovoBiotic Pharmaceuticals, LLC
- Benzothiazinone derivative substituted with trifluoromethyl at 6-position, and preparation method therefor and use thereof14 Jul 2026US 12,679,835 B2Soochow University
- Lactobacillus paracasei ATG-EI strain or composition comprising same for preventing or treating respiratory disease30 Jun 2026US 12,667,598 B2Atogen Co., Ltd
- Nutritional compositions, supplements, and fortifiers8 Oct 2026US 2026/0306432 A1Societe des Produits Nestle S. A.
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
- Rna for preventing or treating tuberculosis24 Sep 2026US 2026/0284168 A1
- Tuberculosis vaccine composition containing immune-active site fusion protein10 Sep 2026US 2026/0263577 A1Myco-Rapha Inc.
- Composition for preventing, ameliorating, or treating tuberculosis comprising extract of philadelphus sp. plant as active ingredient3 Sep 2026US 2026/0256859 A1Chungnam National University Hospital
Most cited
By later US patents
- Downmodulating an immune response with multivalent antibodies to PD-1309US 6,808,710 B1Dana-Farber Cancer Institute, Inc. · 2004
- Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components256US 9,345,780 B2Tekmira Pharmaceuticals Corporation · 2016
- Imidazonaphthyridines255US 6,194,425 B13M Innovative Properties Company · 2001
- Thioether substituted imidazoquinolines177US 6,664,264 B23M Innovative Properties Company · 2003
- Methods and compositions involving miRNA and miRNA inhibitor molecules171US 9,506,061 B2Asuragen, Inc. · 2016